GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

The pharmaceutical industry is poised for an opportunity to tweak parts of the Medicare drug pricing negotiation law, after ...

Kennedy Jr. has his way, get ready for even more anti-pharma rhetoric and potential instability at the Food and Drug ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

There’s no better time to be alive, only if we can learn to thrive amidst constant change and disruption” muses health tech ...

When Hurricane Helene damaged western North Carolina in September, filling medical facilities with people who couldn't be ...

Drugmaker Abbott India reported a rise in second-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications. The company, which makes the ...

Several companies such as Shriram Finance, Symphony, etc. will be in focus today on account of corporate actions.

Dividend, stock split: Navin Fluorine International, Nuvama Wealth Management, Share India Securities, Shriram Finance Ltd, ...

Report on how AI is redefining market landscape - The global gastroparesis drugs market size is estimated to grow by USD 1.42 ...

The growing demand for alopecia treatments is mainly driven by the rising global prevalence of alopecia, influenced by various factors, as well as increasing research and development efforts in ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...